ISResearchers from the Technion-Israel Institute of Technology have developed nanoparticles capable of treating triple-negative breast cancer without the need for medication or drugs, potentially offering a drug-free treatment approach for this aggressive form of breast cancer. The study, published in the journal ACS Nano, demonstrated success in laboratory tests using mouse models. The research was led by doctoral student Ofri Vizenblit with assistance from Rawan Mhajne, under the supervision of Professor Assaf Zinger. Zinger expressed hope that the technology could move into clinical trials on
Bias read (Center): The article reports on scientific research with no apparent political framing. It focuses on medical advancements and does not take a stance on political issues.
Why these scores (Factual 95 · Objective 90): The article presents accurate details about the research conducted by Technion-Israel scientists, citing specific names, roles, and results from their study published in ACS Nano. It accurately quotes Zinger and provides context about triple-negative breast cancer. The only minor deduction is due to
